Lowest Price Guaranteed
Pages
242
Last Updated
June 2026
View Count
12362
Chapter 2 presents an executive summary of the report. It offers a high level view on where the ubiquitin enzyme inhibitors market is headed in the mid-long term.
Chapter 3 provides a general introduction to the underlying concepts of protein homeostasis, emphasizing on the importance of post translational modifications in cellular processes. The chapter covers details on the discovery of the UPS, the structure and function of ubiquitin, brief discussions on the various components of the UPS, fundamentals of the UPS machinery and a schematic representation of the ubiquitination process. In addition, we have discussed the therapeutic applications of the UPS, providing the necessary arguments and evidence supporting the gradual replacement of the currently available proteasome inhibitor based therapies with the emerging class of ubiquitin enzyme inhibitors.
Chapter 4 provides a comprehensive overview of the current landscape of the ubiquitin enzyme inhibitors market. It includes information on the potential drug candidates that are currently in different stages of development (both clinical and preclinical / discovery). It presents a detailed analysis of the pipeline of products in this domain, including information on the most commonly targeted indications, current phases of development, target enzyme classes and key players involved in this space. Additionally, we have provided details of several research platforms, precursor compounds and research tools developed / being developed by various companies in order to support R&D initiatives in this space.
Chapter 5 presents important insights extracted from the current pipeline. The chapter provides a grid analysis of the candidate drugs in the market based on their distribution by target enzyme class, therapeutic area and highest phase of development. It also highlights the most popular targets within the UPS pathway from among the four ubiquitin enzyme classes mentioned earlier. In addition, we have also included an overview of the developer landscape based on the size and the activity of the industrial / non-industrial players engaged in this market. Along with that, we have mapped the geographical presence of various companies involved in the clinical development of product candidates in this field.
Chapter 6 focuses on E1 activating enzyme and E2 conjugating enzyme based inhibitors. The chapter includes a brief discussion on the role of these enzymes in the UPS pathway, including their mechanisms of action, important enzyme families, targets under investigation, current challenges and opportunities, and other relevant parameters. The chapter also includes detailed profiles of advanced stage product candidates. Each profile covers information such as drug specifications, its mechanism of action, current status of development, ongoing / completed clinical studies, key preclinical / clinical findings and other associated details.
Chapter 7 provides in-depth information on E3 ligases. The chapter includes a brief discussion on the role of E3 ligases in the UPS pathway, including its mechanism of action, important enzyme families, targets under investigation, current challenges and opportunities, details of screening assays and other relevant parameters. The chapter also includes detailed profiles of advanced stage product candidates. Each profile covers information such as drug specifications, its mechanism of action, current status of development, ongoing / completed clinical studies, key preclinical / clinical findings and other associated details.
Chapter 8 elaborates on DUB enzyme inhibitors. As in earlier two chapters, it discusses the role of DUBs in the UPS pathway, including its mechanism of action, important enzyme families, targets under investigation, current challenges and opportunities, details of screening assays and other relevant parameters. The chapter also includes detailed profiles of the drugs under advanced stages of development.
Chapter 9 provides details on the various drug classes that are closely related to the UPS; these include proteasome inhibitors, immunomodulatory drugs (IMiDs) and inhibitors of apoptosis proteins (IAP inhibitors). In this section, we have provided a brief introduction to the aforementioned competing drug classes, providing insights into their respective mechanisms of action and an overview of the molecules developed / being developed under each class of drugs.
Chapter 10 presents details on the investments and grants received by companies working in the field of ubiquitin enzymes and other closely associated product candidates. The analysis highlights the growing interest of the venture capital community and other strategic investors in this market.
Chapter 11 features an elaborate discussion on the collaborations and partnerships that have been inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements prevalent in this segment of the overall market.
Chapter 12 provides a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. The analysis takes into consideration the molecules that are in relatively more advanced stages of development (phase I/II, phase II and phase III). The future sales potential and growth opportunity is based on the target patient populations, existing / future competition, likely adoption rates and price points.
Chapter 13 summarizes the overall report. In this chapter, we have provided a recap of the key takeaways from the study and our independent opinion based on the research and analysis described in previous chapters.
Chapter 14 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. We have presented the details provided to us by Martin Wiles (Vice President, Almac Discovery) and Gerald Gavory (Director of Biology, Almac Discovery), Zhihao Zhuang (Associate Professor, Department of Chemistry and Biochemistry, University of Delaware) and Katrin Rittinger (Research Group Leader, Francis Crick Institute).
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Chapter Overview
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. The Concept of Protein Homeostasis
3.3. Importance of Post Translational Modifications in Cellular Functions
3.4. Discovery of the Ubiquitin / Ubiquitin Proteasome System
3.5. Ubiquitin: Structure and Function
3.6. Fundamentals of the UPS
3.6.1. Components of the UPS
3.6.2. Key Steps Involved in the UPS
3.7. Therapeutic Applications of UPS
3.8. Emergence of Ubiquitin Enzyme Inhibitors
4. UBIQUITIN ENZYME INHIBITORS: MARKET OVERVIEW
4.1. Chapter Overview
4.2. Ubiquitin Enzyme Inhibitors: Development Pipeline
4.3. Ubiquitin Enzyme Inhibitors: Distribution by Phase of Development
4.4. Ubiquitin Enzyme Inhibitors: Distribution by Therapeutic Area
4.5. Ubiquitin Enzyme Inhibitors: Distribution by Target Ubiquitin Enzymes
4.6. Ubiquitin Enzyme Inhibitors: Distribution by Geography
4.7. Ubiquitin Enzyme Inhibitors: Most Active Industry Players
4.8. Ubiquitin Enzyme Inhibitors: Research Tools, Key Technologies and Precursor Compounds
4.8.1. Research Tools / Key Technologies
4.8.2. Precursor Compounds
4.8.3. UPS Based Research Tools: Other Players
5. KEY INSIGHTS: THERAPEUTIC AREAS AND POTENTIAL TARGETS
5.1. Chapter Overview
5.2. Ubiquitin Enzyme Inhibitors Clinical Development Analysis: Therapeutic Areas
5.3. Ubiquitin Enzyme Inhibitors Clinical Development Analysis: Potential Targets
5.4. Ubiquitin Enzyme Inhibitors Clinical Development Analysis: Developer Landscape
5.5. Developers of Ubiquitin Enzyme Inhibitors: Geographical Presence
5.6. Ubiquitin Enzyme Inhibitors and UPS: Recent / Upcoming Conferences
6. E1 AND E2 ENZYMES AS THERAPEUTIC TARGETS
6.1. Chapter Overview
6.2. E1 Activating Enzymes as Drug Targets
6.2.1. E1 Enzymes: An Introduction
6.2.2. E1 Enzymes: Mechanism of Action
6.2.3. E1 Enzyme Inhibitors: List of Related Targets
6.2.4. E1 Enzyme Inhibitors: Development Pipeline
6.2.5. E1 Enzyme Inhibitors: Drug Profiles
6.2.6. E1 Enzyme Inhibitors Development: Challenges and Opportunities
6.3. E2 Conjugating Enzymes as Drug Targets
6.3.1. E2 Enzymes: An Introduction
6.3.2. E2 Enzymes: Mechanism of Action
6.3.3. E2 Enzyme Inhibitors: List of Related Targets
6.3.4. E2 Enzyme Inhibitors: Development Pipeline
6.3.5. E2 Enzyme Inhibitors Development: Challenges and Opportunities
7. E3 ENZYMES AS THERAPEUTIC TARGETS
7.1. Chapter Overview
7.2. E3 Ligases: An Introduction
7.3. E3 Ligases: Mechanism of Action
7.4. E3 Ligases: Important Families
7.4.1. The RING Family
7.4.2. The HECT Family
7.4.3. SCF Complex
7.4.4. U-Box Family
7.4.5. RBR Family
7.5. E3 Ligase Inhibitors: List of Related Targets
7.6. E3 Ligase Inhibitors: Screening Methods
7.7. E3 Ligase Inhibitors: Development Pipeline
7.8. E3 Ligase Inhibitors: Drug Profiles
7.8.1. Idasanutlin / RG 7388 / RO 5503781 (Roche)
7.8.1.1. Drug Specifications
7.8.1.2. Mechanism of Action
7.8.1.3. Current Status of Development
7.8.1.4. Key Clinical Trials
7.8.1.5. Key Preclinical / Clinical Findings
7.8.2. AMG 232 (Amgen)
7.8.2.1. Drug Specifications
7.8.2.2. Mechanism of Action
7.8.2.3. Current Status of Development
7.8.2.4. Key Clinical Trials
7.8.2.5. Key Preclinical / Clinical Findings
7.8.3. HDM201 / NVP-HDM201 (Novartis Pharmaceuticals)
7.8.3.1. Drug Specifications
7.8.3.2. Mechanism of Action
7.8.3.3. Current Status of Development
7.8.3.4. Key Clinical Trials
7.8.3.5. Key Preclinical / Clinical Findings
7.9. E3 Ligase Inhibitors: Challenges and Opportunities
8. DUB ENZYMES AS THERAPEUTIC TARGETS
8.1. Chapter Overview
8.2. DUBs: An Introduction
8.3. DUBs: Mechanism of Action
8.4. DUBs: Important Families
8.4.1. USP / UBP Family
8.4.2. UCH Family
8.4.3. MCPIP Family
8.4.4. OTU Family
8.4.5. MJD Family
8.4.6. JAMM Family
8.5. DUB Inhibitors: List of Related Targets
8.6. DUB Inhibitors: Screening Methods
8.7. DUB Inhibitors: Development Pipeline
8.8. DUB Inhibitors: Drug Profiles
8.9. DUB Inhibitors Development: Challenges and Opportunities
9. ASSOCIATED DRUG CLASSES
9.1. Chapter Overview
9.2. Proteasome Inhibitors
9.3. Immunomodulatory Drugs
9.4. IAP Inhibitors
10. VENTURE CAPITAL INTEREST
10.1. Chapter Overview
10.2. Funding Instances: Distribution by Type of Funding
10.3. Funding Instances for Development of Ubiquitin Based Therapeutics
10.4. Rising Venture Capital Interest
10.5. Leading Players: Distribution by Number of Funding Instances
10.6. Most Active Venture Capital Firms / Investors
10.7. Funding Instances: Distribution by Focus Area
11. RECENT COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models / Agreements
11.3. UPS Based Therapeutics: Recent Collaborations
11.4. Recent Collaborations: Distribution by Month / Year
11.5. Recent Collaborations: Distribution by Type of Model
11.6. Recent Collaborations: Distribution by Focus Area
11.7. Recent Collaborations: Most Active Companies
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Scope and Limitations
12.3. Forecast Methodology
12.4. Overall Ubiquitin Enzyme Inhibitors Market
12.5. Ubiquitin Enzyme Inhibitors Market: Individual Forecasts
12.5.1. Idasanutlin (Genentech)
12.5.1.1. Target Patient Population
12.5.1.2. Sales Forecast
12.5.2. Pevonedistat (Millennium Pharmaceuticals)
12.5.2.1. Target Patient Population
12.5.2.2. Sales Forecast
12.5.3. HDM201 (Novartis Pharmaceuticals)
12.5.3.1. Target Patient Population
12.5.3.2. Sales Forecast
12.5.4. VLX1570 (Vivolux)
12.5.4.1. Target Patient Population
12.5.4.2. Sales Forecast
12.5.5. AMG 232 (Amgen)
12.5.5.1. Target Patient Population
12.5.5.2. Sales Forecast
13. CONCLUSION
13.1. Drugs Targeting Protein Modification Pathways Have Emerged as Valuable Therapeutic Options
13.2. Extensive Research is Being Carried Out to Address the Challenges Associated with Drug Discovery
13.3. The Evolving Pipeline Caters to a Wide Spectrum of Disease Indications
13.4. Targeted Therapies are Being Developed by Leveraging Inherent Specificity of Various UPS Components
13.5. Growing Partnerships and VC Support are Indicative of Lucrative Future Potential
13.6. Novel Technology Platforms and Therapeutic Concepts Will Act as Key Enablers to Drive Future Growth
13.7. Once Approved, Ubiquitin Enzyme Inhibitors are Poised to Achieve an Accelerated Growth
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Martin Wiles, Vice President Business Development and Licensing, Almac Discovery
Gerald Gavory, Director of Biology, Almac Discovery
14.3. Katrin Rittinger, Research Group Leader, Francis Crick Institute
14.4. Zhihao Zhuang, Associate Professor, Department of Chemistry and Biochemistry, University Of Delaware
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Protein Surveillance: Important Mechanisms
Figure 3.2 Post Translational Modifications: Common Types
Figure 3.3 Phosphorylation and Ubiquitination: Key Differences in Drug Discovery
Figure 3.4 Phosphorylation and Ubiquitination: Mechanism based Analogies
Figure 3.5 Ubiquitin: Types of Target Proteins
Figure 3.6 Genetic Evolution of the UPS in Eukaryotes
Figure 3.7 Key Components of the UPS
Figure 3.8 Ubiquitin-Proteasome Pathway
Figure 3.9 Modes of Ubiquitination
Figure 3.10 Ubiquitination: Biological Functions
Figure 3.11 UPS: Disease Development Process
Figure 3.12 UPS: Key Therapeutic Areas
Figure 4.1 Ubiquitin Enzyme Inhibitors: Distribution by Phase of Development
Figure 4.2 Ubiquitin Enzyme Inhibitors: Distribution by Therapeutic Area
Figure 4.3 Ubiquitin Enzyme Inhibitors: Distribution by Target Enzymes
Figure 4.4 Ubiquitin Enzyme Inhibitors: Distribution by Target Ubiquitin Enzymes and Phase of Development
Figure 4.5 Ubiquitin Enzyme Inhibitors: Distribution by Geography
Figure 4.6 Ubiquitin Enzyme Inhibitors: Regional Landscape
Figure 4.7 Ubiquitin Enzyme Inhibitors: Most Active Industry Players
Figure 4.8 UPS Based Research Tools: Other Market Participants
Figure 5.1 Grid Analysis: Distribution by Target Enzyme Class, Therapeutic Area and Phase of Development
Figure 5.2 Ubiquitin Enzyme Inhibitors Funnel Analysis: Distribution by Target Enzyme Class and Phase of Development
Figure 5.3 Ubiquitin Enzyme Inhibitors Developer Landscape: Distribution by Developer and Phase of Development
Figure 5.4 Ubiquitin Enzyme Inhibitors: Geographical Presence
Figure 5.5 Recent / Upcoming Conferences: Distribution by Year and Geography
Figure 5.6 Recent / Upcoming Conferences: Regional Map
Figure 6.1 E1 Activating Enzymes: List of Related Targets
Figure 6.2 E1 Enzyme Drug Development: Major Challenges
Figure 6.3 E2 Enzymes: List of Related Targets
Figure 6.4 E2 Enzyme Drug Development: Major Challenges
Figure 7.1 Mechanism of Action: RING, HECT and U-Box Families
Figure 7.2 E3 Ligases: Important Families
Figure 7.3 Tumor Suppression by p53
Figure 7.4 Different Types of MDM2-p53 Interactions
Figure 7.5 MDM2 Mediated p53 Degradation Pathway
Figure 7.6 E3 Ligases: List of Related Targets
Figure 7.7 E3 Ligases: Screening Methods
Figure 7.8 E3 Ligase Drug Development: Major Challenges
Figure 8.1 DUB Enzymes: Important Families
Figure 8.2 DUB Enzymes: List of Related Targets
Figure 8.3 DUB Enzymes: Screening Methods
Figure 8.4 DUB Drug Development: Major Challenges
Figure 9.1 Proteasome Inhibitors: Related Side Effects
Figure 9.2 IAP Pathways and SMAC Mimetics
Figure 10.1 Funding Instances: Number of Instances, 2006-2016
Figure 10.2 Funding Instances: Amount Invested, 2006-2016 (USD Million)
Figure 10.3 Funding Instances: Distribution by Type, 2006-2016
Figure 10.4 Funding Instances: Distribution by Total Amount Invested, 2006-2016 (USD Million)
Figure 10.5 Funding Instances: Distribution by Range of Amount Invested by Type of Funding (USD Million)
Figure 10.6 Most Active Players: Distribution by Number of Funding Instances, 2006-2016
Figure 10.7 Most Active Venture Capital Firms / Investors: Distribution by Number of Instances, 2006-2016
Figure 10.8 Funding Instances: Distribution by Focus Area
Figure 11.1 Recent Collaborations: Distribution by Year
Figure 11.2 Recent Collaborations: Distribution by Type of Model
Figure 11.3 Recent Collaborations: Distribution by Focus Area
Figure 11.4 Recent Collaborations: Distribution by Focus Area and Partnership Model
Figure 11.5 Recent Collaborations: Most Active Players
Figure 12.1 Overall Ubiquitin Enzyme Inhibitors Market (USD Million): 2016-2030 (Base Scenario)
Figure 12.2 Ubiquitin Enzyme Inhibitors Market: Distribution by Therapeutic Area, 2025, 2030 (USD Million)
Figure 12.3 Ubiquitin Enzyme Inhibitors Market: Distribution by Target Enzyme Class, 2030 (USD Million)
Figure 12.4 Ubiquitin Enzyme Inhibitors: Distribution of Market Share, 2030 (USD Million)
Figure 12.5 Idasanutlin Sales Forecast (USD Million), Base Scenario
Figure 12.6 Pevonedistat Sales Forecast (USD Million), Base Scenario
Figure 12.7 HDM201 Sales Forecast (USD Million), Base Scenario
Figure 12.8 VLX1570 Sales Forecast (USD Million), Base Scenario
Figure 12.9 AMG 232 Sales Forecast (USD Million), Base Scenario
Figure 13.1 Overall Ubiquitin Enzyme Inhibitors Market Summary (USD Million):2016, 2023, 2030
Table 3.1 Ubiquitin: Structural Classification
Table 4.1 Ubiquitin Enzyme Inhibitors: Development Pipeline
Table 4.2 Ubiquitin Enzyme Inhibitors: Research Platforms
Table 4.3 Ubiquitin Enzyme Inhibitors: Precursor Compounds
Table 5.1 Ubiquitin Enzyme Inhibitors and UPS: Recent / Future Conferences, 2013-2017
Table 6.1 E1 Enzyme Inhibitors: Development Pipeline
Table 6.2 Pevonedistat: Current Status of Development
Table 6.3 Pevonedistat: Clinical Trials
Table 6.4 E2 based Inhibitors: Development Pipeline
Table 7.1 SCF Complex: Core Components
Table 7.2 E3 Ligase based Therapeutics: Development Pipeline
Table 7.3 Idasanutlin: Current Status of Development
Table 7.4 Idasanutlin: Clinical Trials
Table 7.5 AMG 232: Current Status of Development
Table 7.6 AMG 232: Clinical Trials
Table 7.7 HDM201: Current Status of Development
Table 7.8 HDM201: Clinical Trials
Table 8.1 DUB based Therapeutics: Development Pipeline
Table 8.2 VLX 1570: Current Status of Development
Table 8.3 VLX 1570: Clinical Trials
Table 9.1 Velcade: Case Study
Table 9.2 Kyprolis: Case Study
Table 9.3 Ninlaro: Case Study
Table 9.4 IMiDs: Pipeline
Table 9.5 Thalomid: Case Study
Table 9.6 Revlimid: Case Study
Table 9.7 Pomalyst / Imnovid: Case Study
Table 9.8 Types of IAPs in Human Malignancies
Table 9.9 IAP Inhibitors: Pipeline
Table 9.10 AT 406 / Debio 1143: Case Study
Table 9.11 Birinapant / TL 32711: Case Study
Table 10.1 List of Funding Instances and Investors, 2006-2016
Table 10.2 Types of Funding Instances, 2006-2016
Table 10.3 Amount Invested by Target Class, 2006- 2016 (USD Million)
Table 11.1 Ubiquitin Enzyme Inhibitors and Associated Products: Recent Collaborations (2006-2016)
Table 12.1 Ubiquitin Enzyme Inhibitors: Potential Candidates
Table 12.2 Idasanutlin: Target Patient Population
Table 12.3 Pevonedistat: Target Patient Population
Table 12.4 HDM201: Target Patient Population
Table 12.5 VLX1570: Target Patient Population
Table 12.6 AMG 232: Target Patient Population
Table 15.1 Ubiquitin Enzyme Inhibitors: Distribution by Phase of Development
Table 15.2 Ubiquitin Enzyme Inhibitors: Distribution by Therapeutic Area
Table 15.3 Ubiquitin Enzyme Inhibitors: Distribution by Target Enzymes
Table 15.4 Ubiquitin Enzyme Inhibitors: Distribution by Target Ubiquitin Enzymes and Phase of Development
Table 15.5 Ubiquitin Enzyme Inhibitors: Distribution by Geography
Table 15.6 Ubiquitin Enzyme Inhibitors: Most Active Industry Players
Table 15.7 Recent / Upcoming Conferences: Distribution by Year and Geography
Table 15.8 Funding Instances: Number of Instances, 2006-2016
Table 15.9 Funding Instances: Amount Invested, 2006-2016 (USD Million)
Table 15.10 Funding Instances: Distribution by Type, 2006-2016
Table 15.11 Funding Instances: Distribution by Total Amount Invested, 2006-2016 (USD Million)
Table 15.12 Most Active Players: Distribution by Number of Funding Instances, 2006-2016
Table 15.13 Most Active Venture Capital Firms / Investors: Distribution by Number of Instances, 2006-2016
Table 15.14 Funding Instances: Distribution by Focus Area
Table 15.15 Recent Collaborations: Distribution by Year
Table 15.16 Recent Collaborations: Distribution by Type of Model
Table 15.17 Recent Collaborations: Distribution by Focus Area
Table 15.18 Recent Collaborations: Distribution by Focus Area and Partnership Model
Table 15.19 Recent Collaborations: Most Active Players
Table 15.20 Overall Ubiquitin Enzyme Inhibitors Market (USD Million): 2016-2030 (Base Scenario)
Table 15.21 Overall Ubiquitin Enzyme Inhibitors Market (USD Million): 2016-2030 (Optimistic Scenario)
Table 15.22 Overall Ubiquitin Enzyme Inhibitors Market (USD Million): 2016-2030 (Conservative Scenario)
Table 15.23 Ubiquitin Enzyme Inhibitors: Market Distribution by Therapeutic Area, 2025, 2030 (USD Million)
Table 15.24 Ubiquitin Enzyme Inhibitors: Market Distribution by Target Enzyme Class, 2030 (USD Million)
Table 15.25 Ubiquitin Enzyme Inhibitors: Distribution of Market Share, 2030 (USD Million)
Table 15.26 Idasanutlin Sales Forecast (USD Million), Base Scenario
Table 15.27 Idasanutlin Sales Forecast (USD Million), Optimistic Scenario
Table 15.28 Idasanutlin Sales Forecast (USD Million), Conservative Scenario
Table 15.29 Pevonedistat Sales Forecast (USD Million), Base Scenario
Table 15.30 Pevonedistat Sales Forecast (USD Million), Optimistic Scenario
Table 15.31 Pevonedistat Sales Forecast (USD Million), Conservative Scenario
Table 15.32 HDM201 Sales Forecast (USD Million), Base Scenario
Table 15.33 HDM201 Sales Forecast (USD Million), Optimistic Scenario
Table 15.34 HDM201 Sales Forecast (USD Million), Conservative Scenario
Table 15.35 VLX1570 Sales Forecast (USD Million), Base Scenario
Table 15.36 VLX1570 Sales Forecast (USD Million), Optimistic Scenario
Table 15.37 VLX1570 Sales Forecast (USD Million), Conservative Scenario
Table 15.38 AMG 232 Sales Forecast (USD Million), Base Scenario
Table 15.39 AMG 232 Sales Forecast (USD Million), Optimistic Scenario
Table 15.40 AMG 232 Sales Forecast (USD Million), Conservative Scenario
Table 15.41 Ubiquitin Enzyme Inhibitors Market Summary (USD Million): 2016, 2023, 2030
The following companies and organizations have been mentioned in the report.